Overview Dividends

(GRAL) GRAIL - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3847471014

Cancer Screening, Diagnostic Aid, Development Services, Minimal Residual Disease

Risk via 10d forecast
Volatility 97.1%
Value at Risk 5%th 140%
Relative Tail Risk -12.66%
Reward TTM
Sharpe Ratio 2.06
Alpha 487.64
Character TTM
Hurst Exponent 0.359
Beta 2.463
Beta Downside 2.580
Drawdowns 3y
Max DD 61.12%
Mean DD 25.07%
Median DD 26.26%

Description: GRAL GRAIL November 15, 2025

GRAIL, Inc. (NASDAQ: GRAL) is a commercial-stage biotech firm that commercializes multi-cancer early-detection tests, most notably Galleri-a blood-based screening assay for asymptomatic adults ≥ 50 years-and DAC, a diagnostic-aid platform that speeds resolution for patients with a clinical suspicion of cancer. The company also offers development services for clinical studies, pilot programs, and therapy-development collaborations, and it is advancing minimal residual disease (MRD) assays to monitor disease recurrence after treatment.

Since its 2015 incorporation in Menlo Park, California, GRAIL has leveraged its deep sequencing and data-analytics capabilities to address a $5 billion U.S. market projected to grow at ~10 % CAGR, driven by an aging population and expanding Medicare coverage for Galleri (added in 2023). In Q2 2024 the firm reported $78 million in revenue, a 42 % YoY increase, and held $420 million in cash, giving it roughly 18 months of runway at current burn rates. Competitive pressures from Guardant Health and Exact Sciences, as well as the need for broader payer acceptance, remain key risk factors.

For a deeper quantitative dive, you might explore ValueRay’s analyst page on GRAL to see the latest consensus estimates and risk metrics.

GRAL Stock Overview

Market Cap in USD 2,999m
Sub-Industry Biotechnology
IPO / Inception 2024-06-25
Return 12m vs S&P 500 407%
Analyst Rating 3.50 of 5

GRAL Dividends

Currently no dividends paid

GRAL Growth Ratios

Metric Value
CAGR 3y 176.08%
CAGR/Max DD Calmar Ratio 2.88
CAGR/Mean DD Pain Ratio 7.02
Current Volume 1574.3k
Average Volume 979.5k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-406.2m TTM) > 0 and > 6% of Revenue (6% = 8.51m TTM)
FCFTA -0.14 (>2.0%) and ΔFCFTA 7.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 361.0% (prev 693.0%; Δ -332.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.14 (>3.0%) and CFO -370.0m > Net Income -406.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (36.1m) change vs 12m ago 13.31% (target <= -2.0% for YES)
Gross Margin -69.92% (prev -68.59%; Δ -1.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 4.96% (prev 3.77%; Δ 1.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.76 (EBITDA TTM -400.8m / Interest Expense TTM 145.0m) >= 6 (WARN >= 3)

Altman Z'' -41.72

(A) 0.20 = (Total Current Assets 589.4m - Total Current Liabilities 77.4m) / Total Assets 2.60b
(B) -3.89 = Retained Earnings (Balance) -10.11b / Total Assets 2.60b
warn (B) unusual magnitude: -3.89 — check mapping/units
(C) -0.14 = EBIT TTM -400.0m / Avg Total Assets 2.86b
(D) -28.00 = Book Value of Equity -10.11b / Total Liabilities 361.1m
Total Rating: -41.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.15

1. Piotroski 0.0pt
2. FCF Yield -14.77%
3. FCF Margin data missing
4. Debt/Equity 0.03
5. Debt/Ebitda 0.17
6. ROIC - WACC (= -27.24)%
7. RoE -17.16%
8. Rev. Trend 88.59%
9. EPS Trend 70.51%

What is the price of GRAL shares?

As of November 21, 2025, the stock is trading at USD 85.65 with a total of 1,574,296 shares traded.
Over the past week, the price has changed by +2.94%, over one month by -6.75%, over three months by +166.24% and over the past year by +467.59%.

Is GRAL a buy, sell or hold?

GRAIL has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold GRAL.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the GRAL price?

Issuer Target Up/Down from current
Wallstreet Target Price 61.5 -28.2%
Analysts Target Price 61.5 -28.2%
ValueRay Target Price 100.8 17.7%

GRAL Fundamental Data Overview November 15, 2025

Market Cap USD = 3.00b (3.00b USD * 1.0 USD.USD)
P/S = 22.4046
P/B = 1.3202
Beta = None
Revenue TTM = 141.8m USD
EBIT TTM = -400.0m USD
EBITDA TTM = -400.8m USD
Long Term Debt = 68.1m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 58.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -68.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.52b USD (3.00b + Debt 58.6m - CCE 540.1m)
Interest Coverage Ratio = -2.76 (Ebit TTM -400.0m / Interest Expense TTM 145.0m)
FCF Yield = -14.77% (FCF TTM -371.8m / Enterprise Value 2.52b)
FCF Margin = -262.1% (FCF TTM -371.8m / Revenue TTM 141.8m)
Net Margin = -286.4% (Net Income TTM -406.2m / Revenue TTM 141.8m)
Gross Margin = -69.92% ((Revenue TTM 141.8m - Cost of Revenue TTM 241.0m) / Revenue TTM)
Gross Margin QoQ = 56.04% (prev -50.01%)
Tobins Q-Ratio = 0.97 (Enterprise Value 2.52b / Total Assets 2.60b)
Interest Expense / Debt = 247.5% (Interest Expense 145.0m / Debt 58.6m)
Taxrate = 25.05% (-29.7m / -118.7m)
NOPAT = -299.8m (EBIT -400.0m * (1 - 25.05%)) [loss with tax shield]
Current Ratio = 7.61 (Total Current Assets 589.4m / Total Current Liabilities 77.4m)
Debt / Equity = 0.03 (Debt 58.6m / totalStockholderEquity, last quarter 2.24b)
Debt / EBITDA = 0.17 (negative EBITDA) (Net Debt -68.3m / EBITDA -400.8m)
Debt / FCF = 0.18 (negative FCF - burning cash) (Net Debt -68.3m / FCF TTM -371.8m)
Total Stockholder Equity = 2.37b (last 4 quarters mean from totalStockholderEquity)
RoA = -15.62% (Net Income -406.2m / Total Assets 2.60b)
RoE = -17.16% (Net Income TTM -406.2m / Total Stockholder Equity 2.37b)
RoCE = -16.42% (EBIT -400.0m / Capital Employed (Equity 2.37b + L.T.Debt 68.1m))
RoIC = -12.44% (negative operating profit) (NOPAT -299.8m / Invested Capital 2.41b)
WACC = 14.80% (E(3.00b)/V(3.06b) * Re(15.09%) + (debt cost/tax rate unavailable))
Discount Rate = 15.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.86%
Fair Price DCF = unknown (Cash Flow -371.8m)
EPS Correlation: 70.51 | EPS CAGR: 5575 % | SUE: 0.67 | # QB: 0
Revenue Correlation: 88.59 | Revenue CAGR: 27.69% | SUE: N/A | # QB: 0

Additional Sources for GRAL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle